European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Evidence-Based Recommendations for Rotavirus Vaccination in Europe

摘要

Two live vaccines against rotavirus gastroenteritis (RVGE) were approved by the European Medicines Agency in 2006: oral live attenuated human rotavirus (RV) vaccine (RIX4414, Rotarix; GlaxoSmithKline Bio-logicals, Rixensart, Belgium) and oral live human-bovine reassortant RV vaccine (RotaTeq; Sanofi Pasteur MSD, Lyon, France).As of October 2007, Rotarix had been licensed in 102 countries with applications submitted to 18 others, and RotaTeq had been licensed in more than 61 countries with applications submitted to 131 others. In at least 5 countries, Rotarix is used in a national immunisation programme (Brazil, El Salvador, Mexico, Panama, and Venezuela), and RotaTeq is used for universal immunisation in the United States (1,2). In Europe, as of February 2007, Austria, Belgium, and Luxembourg had made recommendations for universal RV vaccination.